Fulgent Genetics, Inc. $FLGT Shares Purchased by Quantinno Capital Management LP

Quantinno Capital Management LP boosted its holdings in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) by 374.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 137,479 shares of the company’s stock after acquiring an additional 108,519 shares during the quarter. Quantinno Capital Management LP owned about 0.46% of Fulgent Genetics worth $2,186,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in FLGT. Farther Finance Advisors LLC lifted its stake in shares of Fulgent Genetics by 69.3% in the 4th quarter. Farther Finance Advisors LLC now owns 1,339 shares of the company’s stock valued at $35,000 after purchasing an additional 548 shares during the last quarter. Kestra Advisory Services LLC purchased a new stake in Fulgent Genetics in the 4th quarter valued at about $35,000. Caitong International Asset Management Co. Ltd lifted its position in Fulgent Genetics by 214.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,834 shares of the company’s stock valued at $48,000 after buying an additional 1,251 shares during the last quarter. Flagship Harbor Advisors LLC acquired a new position in Fulgent Genetics in the fourth quarter valued at about $56,000. Finally, Raymond James Financial Inc. purchased a new position in Fulgent Genetics during the second quarter worth about $49,000. Hedge funds and other institutional investors own 48.06% of the company’s stock.

Insider Activity

In related news, COO Jian Xie sold 2,146 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $17.89, for a total transaction of $38,391.94. Following the sale, the chief operating officer directly owned 367,605 shares in the company, valued at approximately $6,576,453.45. This represents a 0.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Hanlin Gao sold 1,688 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $17.89, for a total transaction of $30,198.32. Following the completion of the sale, the insider directly owned 990,374 shares in the company, valued at approximately $17,717,790.86. This trade represents a 0.17% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 5,980 shares of company stock valued at $106,360 in the last quarter. Company insiders own 36.18% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Fulgent Genetics in a research note on Monday, July 6th. Piper Sandler lifted their target price on shares of Fulgent Genetics from $15.00 to $19.00 and gave the company a “neutral” rating in a report on Tuesday, August 4th. Finally, Wall Street Zen lowered Fulgent Genetics from a “sell” rating to a “strong sell” rating in a research report on Saturday. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Fulgent Genetics has a consensus rating of “Hold” and a consensus target price of $27.50.

Fulgent Genetics Stock Down 0.4%

NASDAQ:FLGT opened at $19.06 on Tuesday. Fulgent Genetics, Inc. has a 52 week low of $13.46 and a 52 week high of $31.04. The company has a fifty day simple moving average of $19.39 and a two-hundred day simple moving average of $18.78. The company has a market cap of $524.34 million, a price-to-earnings ratio of -6.76 and a beta of 0.91.

Fulgent Genetics (NASDAQ:FLGT) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.12). Fulgent Genetics had a negative net margin of 26.05% and a negative return on equity of 4.93%. The company had revenue of $85.39 million during the quarter, compared to analyst estimates of $94.00 million. Fulgent Genetics has set its FY 2026 guidance at -2.350–2.220 EPS. On average, analysts expect that Fulgent Genetics, Inc. will post -2.81 EPS for the current year.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.